Plain-English translation of NCT07273409 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether surgery to remove most of a pancreatic neuroendocrine tumor, followed by standard cancer medications, helps people live longer than medication treatment alone. Pancreatic neuroendocrine tumors are rare cancers that start in the hormone-producing cells of the pancreas, and many patients are diagnosed after the cancer has already spread to other parts of the body. The study will randomly assign participants to either the surgery-plus-medication group or the medication-only group to find out which approach is better.
Doctors are not sure whether aggressive surgery to shrink tumors helps people with advanced pancreatic neuroendocrine tumors live longer or have better quality of life. This trial exists to answer that important question so doctors can give patients the best treatment option.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the surgery group, you will have surgery to remove as much of the tumor as possible, followed by standard cancer medications and follow-up care—with the option for additional surgery later if needed to reduce tumor burden. If you are assigned to the medication-only group, you will receive standard cancer medications without planned surgery, though your doctors can perform surgery later if it becomes medically necessary. Either way, you will have regular follow-up visits and tests to monitor your health, quality of life, and how you are doing over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Sweden